# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
nours per response	e 0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)		_												
1. Name and Address of Reporting Person * Haqq Christopher				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
611 GATEWAY BOULEVARD, SUITE 900					3. Date of Earliest Transaction (Month/Day/Year) 02/09/2017							X Officer (give title below) Other (specify below) EVP, R&D & Chief Scientific Of				
(Street) SOUTH SAN FRANCISCO, CA 94080			4. If Am	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City	7)	(State)	(Zip)		Ta	able I - N	on-Der	ivative S	ecuriti	es Acqu	ired, Disp	osed of, or	Beneficially	Owned		
1.Title of S (Instr. 3)	Date Execution Date, if		f Code (Instr.		A. Securities Acquired (A) or Disposed of (D (Instr. 3, 4 and 5)						6. Ownership Form: Direct (D) or Indirect (I)	Beneficial Ownership				
						Code	· V	Amoun		Price				(Instr. 4)		
Common	Stock		02/09/2017			S(1)		13,975	D	\$ 15.46 (2)	399,630	)		D		
Common	Stock										17,312			I	See footnote (3)	
Common	Stock										2,688			I	See footnote (4)	
			Table II -				con the ired, E	tained i form dis	n this isplays	form ai a curre	re not req ently validation	uired to red d OMB co	nformation espond un ntrol numb	less	EC 1474 (9- 02)	
	2. 3. Transaction Conversion Date or Exercise Price of Derivative Security		n 3A. Deemed Execution D any	e.g., puts, calls, was 4. ate, if Transaction Code (Instr. 8)		5. Number 6		and Expiration Da (Month/Day/Year		able 7. T Date Am ear) Und Sec	Fitle and nount of derlying purities str. 3 and		f 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect	Ownershi (Instr. 4)	
				C	ode V	(A) (		te ercisable	Expirat Date	tion Tit	Amount or le Number of Shares					
Repor	ting O	wners														
Reno	rting Owner	· Name / Add	Iress			Relati	onships	S								
Reporting Owner Name / Address  Director  Haqq Christopher 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN ERANCISCO, CA 94080			or 10% Ov		EVP, R&	D & 0	Chief Sc	ientifi		Other						

### **Signatures**

/s/ Tina Gullotta, Attorney-in-Fact for Christopher Haqq	02/10/2017		
**Signature of Reporting Person	Date		

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$15.15 to \$15.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (3) The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
- (4) The shares are held by The Havenside Trust, of which the Reporting Person is trustee.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.